Persistent Post-Recovery Hyperinflammation of Necrotizing Enterocolitis Is Ameliorated by 5-ASA Treatment.

Area of Science:

• Neonatal research
• Gastroenterology
• Inflammation studies

Background:

• Necrotizing enterocolitis (NEC) is a primary cause of mortality in premature infants.
• A persistent hyperinflammatory state is observed in NEC survivors post-recovery.
• The potential for a reduced inflammatory response with anti-inflammatory treatment in recovered NEC patients is unexplored.

Purpose of the Study:

• To investigate the efficacy of mesalamine (5-ASA) in mitigating hyperinflammation in NEC models.
• To assess the impact of 5-ASA on inflammatory markers in both in vitro enteroid and in vivo mouse models of NEC.
• To determine if 5-ASA can reduce the inflammatory response in recovered NEC enteroids upon subsequent NEC induction.

Main Methods:

• Generation of human enteroids for in vitro NEC induction.
• Treatment of enteroids with 5-ASA during NEC induction.
• In vivo NEC induction in mice with pre-treatment of 5-ASA.
• Evaluation of inflammatory markers (TNF-α, IL-8) using RT-qPCR.
• Histological assessment of intestinal tissue in mice.

Main Results:

• 5-ASA treatment significantly decreased inflammatory markers (TNF-α, IL-8) in both recovered and active NEC enteroids.
• In vivo NEC induction in mice pre-treated with 5-ASA showed a significant reduction in TNF-α and IL-8 levels.
• Histological grading in mice also indicated a reduction in NEC severity with 5-ASA treatment.

Conclusions:

• Mesalamine (5-ASA) effectively reduces key inflammatory markers in both in vitro and in vivo models of necrotizing enterocolitis.
• These findings suggest that 5-ASA may be a potential therapeutic agent for managing NEC, particularly in patients with a history of the condition.
• The anti-inflammatory effects of 5-ASA could be crucial in managing the persistent hyperinflammatory state observed post-NEC recovery, potentially altering disease trajectory.